Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Reforgene Biotech Completes $15 Million Pre-B Round for Gene Editing Drugs

publication date: May 12, 2023

Guangzhou Reforgene Biotechnology closed a $15 million Pre-B financing for its portfolio of gene editing candidates, including a clinical stage therapy for thalassemia. In a Phase I trial, the company’s lead β-thalassemia gene-editing drug, RM-001, produced a 100% cure rate. In addition, Reforgene is developing in vivo gene editing therapies for major genetic diseases in the fields of ophthalmology, nervous system and other fields. The financing was led by Yuexiu Industrial Fund with participation by Yuanyin Venture Capital, Shanfeng Venture Capital, Xinxing Fund, Hong Kong and Guangdong Capital, and Guoju Venture Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital